Neovascular age-related macular degeneration

12 trials 3 recruiting MedDRA PT
12 Registered trials
3 Recruiting
9 Unique sponsors
6 Unique IMPs
11 Commercial trials
Drug classes (ATC)
S Ophthalmology/ENT (ATC S) 9
— ATC code not specified 2
L Oncology (ATC L) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 3 substances
Monoclonal antibody 2 substances
Receptor fusion protein 1 substance
Phase III: 6 Phase II: 2 Phase III/IV: 3 Phase IV: 1

Filter these 12 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 12 trials

Phase III

6 trials
  • 4d Molecular Therapeutics Inc. Commercial
    AFLIBERCEPT; ZUNIBERGENE ROCPARVOVEC
    2025-521349-25-00 9 countries 2025 n=298
    Recruiting
  • AbbVie Deutschland GmbH & Co. KG Commercial
    AFLIBERCEPT; RANIBIZUMAB; SURABGENE LOMPARVOVEC
    2023-503666-23-00 5 countries 2024 n=88
    Ended
  • Alvotech Swiss AG Commercial
    AFLIBERCEPT
    2023-505225-13-00 1 country 2024 n=23
    Ended
  • Opthea Limited Commercial
    RANIBIZUMAB; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 3 EXTRACELLULAR DOMAINS 1-3 FUSED TO A IGG1 FC FRAGMENT
    2024-512879-13-00 10 countries 2021 n=298
    Ended
  • Opthea Limited Commercial
    AFLIBERCEPT; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 3 EXTRACELLULAR DOMAINS 1-3 FUSED TO A IGG1 FC FRAGMENT
    2024-512880-30-00 16 countries 2021 n=475
    Ended
  • Rophibio Inc. Commercial
    AFLIBERCEPT
    2023-509206-29-00 4 countries n=289
    Ended

Phase II

2 trials
  • AbbVie Deutschland GmbH & Co. KG Commercial
    SURABGENE LOMPARVOVEC
    2023-505750-17-00 5 countries n=84
    Pending
  • Samsung Bioepis Co. Ltd. Commercial
    RANIBIZUMAB
    2025-520599-24-00 1 country 2026 n=30
    Ended

Phase III/IV

3 trials
  • AbbVie Deutschland GmbH & Co. KG Commercial
    RANIBIZUMAB; SURABGENE LOMPARVOVEC
    2024-512298-28-00 13 countries 2025 n=272
    Recruiting
  • F. Hoffmann-La Roche AG Commercial
    FARICIMAB
    2024-517545-13-00 4 countries 2025 n=89
    Recruiting
  • Medical University Of Graz Academic
    IMP not specified
    2024-515497-26-00 1 country 2024 n=33
    Ended

Phase IV

1 trial
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
AbbVie Deutschland GmbH & Co. KG Commercial 3 Phase III/IV, Phase II, Phase III 1
Opthea Limited Commercial 2 Phase III 0
F. Hoffmann-La Roche AG Commercial 1 Phase III/IV 1
Samsung Bioepis Co. Ltd. Commercial 1 Phase II 0
4d Molecular Therapeutics Inc. Commercial 1 Phase III 1
Alvotech Swiss AG Commercial 1 Phase III 0
Rophibio Inc. Commercial 1 Phase III 0
Bayer AG Commercial 1 Phase IV 0
Medical University Of Graz Academic 1 Phase III/IV 0
New trials by year
2021
2
2024
4
2025
3
2026
1
← All indication landscapes